vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Emerald Holding, Inc. (EEX). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $132.7M, roughly 1.9× Emerald Holding, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -22.8%, a 33.9% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 24.3%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $11.7M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -0.3%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
TVS Emerald Haven Realty Limited is an Indian real estate development company headquartered in Chennai, Tamil Nadu. A subsidiary of TVS Holdings, it specializes in sustainable residential communities and urban development projects.
ANIP vs EEX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $132.7M |
| Net Profit | $27.5M | $-30.2M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | -11.8% |
| Net Margin | 11.1% | -22.8% |
| Revenue YoY | 29.6% | 24.3% |
| Net Profit YoY | 367.5% | -692.2% |
| EPS (diluted) | $1.14 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $132.7M | ||
| Q3 25 | $227.8M | $77.5M | ||
| Q2 25 | $211.4M | $105.5M | ||
| Q1 25 | $197.1M | $147.7M | ||
| Q4 24 | $190.6M | $106.8M | ||
| Q3 24 | $148.3M | $72.6M | ||
| Q2 24 | $138.0M | $86.0M | ||
| Q1 24 | $137.4M | $133.4M |
| Q4 25 | $27.5M | $-30.2M | ||
| Q3 25 | $26.6M | $-14.4M | ||
| Q2 25 | $8.5M | $-1.4M | ||
| Q1 25 | $15.7M | $15.3M | ||
| Q4 24 | $-10.3M | $5.1M | ||
| Q3 24 | $-24.2M | $-11.1M | ||
| Q2 24 | $-2.3M | $-2.8M | ||
| Q1 24 | $18.2M | $11.0M |
| Q4 25 | 14.1% | -11.8% | ||
| Q3 25 | 15.9% | -10.1% | ||
| Q2 25 | 6.6% | 9.7% | ||
| Q1 25 | 13.3% | 24.2% | ||
| Q4 24 | -2.3% | 19.5% | ||
| Q3 24 | -13.8% | -6.5% | ||
| Q2 24 | 3.7% | 7.4% | ||
| Q1 24 | 14.8% | 18.2% |
| Q4 25 | 11.1% | -22.8% | ||
| Q3 25 | 11.7% | -18.6% | ||
| Q2 25 | 4.0% | -1.3% | ||
| Q1 25 | 8.0% | 10.4% | ||
| Q4 24 | -5.4% | 4.8% | ||
| Q3 24 | -16.3% | -15.3% | ||
| Q2 24 | -1.7% | -3.3% | ||
| Q1 24 | 13.2% | 8.2% |
| Q4 25 | $1.14 | $-0.15 | ||
| Q3 25 | $1.13 | $-0.07 | ||
| Q2 25 | $0.36 | $-0.01 | ||
| Q1 25 | $0.69 | $0.08 | ||
| Q4 24 | $-0.45 | $0.01 | ||
| Q3 24 | $-1.27 | $-0.05 | ||
| Q2 24 | $-0.14 | $-0.03 | ||
| Q1 24 | $0.82 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $100.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $338.8M |
| Total Assets | $1.4B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $100.9M | ||
| Q3 25 | $262.6M | $95.4M | ||
| Q2 25 | $217.8M | $156.4M | ||
| Q1 25 | $149.8M | $276.8M | ||
| Q4 24 | $144.9M | $194.8M | ||
| Q3 24 | $145.0M | $188.9M | ||
| Q2 24 | $240.1M | $193.2M | ||
| Q1 24 | $228.6M | $186.8M |
| Q4 25 | $540.7M | $338.8M | ||
| Q3 25 | $505.8M | $369.5M | ||
| Q2 25 | $436.8M | $389.4M | ||
| Q1 25 | $418.6M | $392.1M | ||
| Q4 24 | $403.7M | $385.9M | ||
| Q3 24 | $405.9M | $391.1M | ||
| Q2 24 | $455.8M | $407.6M | ||
| Q1 24 | $452.0M | $-90.7M |
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.0B | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $12.3M |
| Free Cash FlowOCF − Capex | $29.1M | $11.7M |
| FCF MarginFCF / Revenue | 11.8% | 8.8% |
| Capex IntensityCapex / Revenue | 0.5% | 0.5% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $41.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $12.3M | ||
| Q3 25 | $44.1M | $1.8M | ||
| Q2 25 | $75.8M | $15.9M | ||
| Q1 25 | $35.0M | $12.6M | ||
| Q4 24 | $15.9M | $20.6M | ||
| Q3 24 | $12.5M | $9.1M | ||
| Q2 24 | $17.4M | $9.8M | ||
| Q1 24 | $18.3M | $7.3M |
| Q4 25 | $29.1M | $11.7M | ||
| Q3 25 | $38.0M | $1.5M | ||
| Q2 25 | $71.8M | $15.8M | ||
| Q1 25 | $32.5M | $12.4M | ||
| Q4 24 | $13.5M | $19.9M | ||
| Q3 24 | $7.7M | $9.0M | ||
| Q2 24 | $13.0M | $9.6M | ||
| Q1 24 | $13.7M | $7.0M |
| Q4 25 | 11.8% | 8.8% | ||
| Q3 25 | 16.7% | 1.9% | ||
| Q2 25 | 34.0% | 15.0% | ||
| Q1 25 | 16.5% | 8.4% | ||
| Q4 24 | 7.1% | 18.6% | ||
| Q3 24 | 5.2% | 12.4% | ||
| Q2 24 | 9.4% | 11.2% | ||
| Q1 24 | 10.0% | 5.2% |
| Q4 25 | 0.5% | 0.5% | ||
| Q3 25 | 2.7% | 0.4% | ||
| Q2 25 | 1.9% | 0.1% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 1.3% | 0.7% | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | 0.2% | ||
| Q1 24 | 3.3% | 0.2% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 0.82× | ||
| Q4 24 | — | 4.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | 0.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
EEX
| Connections Segment | $121.9M | 92% |
| Commerce Segment | $5.5M | 4% |
| Content | $5.3M | 4% |
